Back to results
US 8,540,977 B2Granted
IL-11 muteins
AssigneeCSL Limited
InventorManuel Baca
Life of this patent
Estimating the term…
Abstract
The present invention relates generally to the treatment of an interleukin-11 (IL-11)-mediated condition. More particularly, the present invention provides the use of modified forms of IL-11 which modulate IL-11 signaling in the treatment of IL-11-mediated conditions.
Claims12
A human IL-11 mutein comprising:
- i. an amino acid sequence that has at least 95% identity to amino acids 10 to 175 of SEQ ID NO:11;
- and
- ii. the amino acid sequence PAIDY (SEQ ID NO:24) at the amino acid positions of said mutein that correspond to positions 58 to 62 of SEQ ID NO:11.
A human IL-11 mutein comprising:
- i. an amino acid sequence that has at least 95% identity to amino acids 10 to 178 of SEQ ID NO:11;
- and
- ii. the amino acid sequence PAIDY (SEQ ID NO:24) at the amino acid positions of said mutein that correspond to positions 58 to 62 of SEQ ID NO:11.
Dependencies are inferred from the claim text.